CN107324399B - A kind of iron oxide nano material and the purposes as tumour medicine targeting carrier - Google Patents
A kind of iron oxide nano material and the purposes as tumour medicine targeting carrier Download PDFInfo
- Publication number
- CN107324399B CN107324399B CN201710564413.6A CN201710564413A CN107324399B CN 107324399 B CN107324399 B CN 107324399B CN 201710564413 A CN201710564413 A CN 201710564413A CN 107324399 B CN107324399 B CN 107324399B
- Authority
- CN
- China
- Prior art keywords
- nano material
- iron oxide
- oxide nano
- butylidenebis
- imidazoles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 title claims abstract description 64
- 239000002086 nanomaterial Substances 0.000 title claims abstract description 35
- 239000003814 drug Substances 0.000 title abstract description 16
- 206010028980 Neoplasm Diseases 0.000 title abstract description 11
- 230000008685 targeting Effects 0.000 title description 4
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 32
- 238000001354 calcination Methods 0.000 claims abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- VFNGKCDDZUSWLR-UHFFFAOYSA-L disulfate(2-) Chemical compound [O-]S(=O)(=O)OS([O-])(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-L 0.000 claims abstract description 15
- 238000006243 chemical reaction Methods 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 13
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 13
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 13
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 13
- 208000032839 leukemia Diseases 0.000 claims abstract description 12
- 238000001027 hydrothermal synthesis Methods 0.000 claims abstract description 11
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 claims abstract description 10
- 239000003937 drug carrier Substances 0.000 claims abstract description 9
- 238000000227 grinding Methods 0.000 claims abstract description 8
- 239000012153 distilled water Substances 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 238000005406 washing Methods 0.000 claims description 12
- 229940044631 ferric chloride hexahydrate Drugs 0.000 claims description 10
- NQXWGWZJXJUMQB-UHFFFAOYSA-K iron trichloride hexahydrate Chemical group O.O.O.O.O.O.[Cl-].Cl[Fe+]Cl NQXWGWZJXJUMQB-UHFFFAOYSA-K 0.000 claims description 10
- 239000008367 deionised water Substances 0.000 claims description 7
- 229910021641 deionized water Inorganic materials 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 235000019441 ethanol Nutrition 0.000 claims description 6
- 239000013049 sediment Substances 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 abstract description 18
- 230000035484 reaction time Effects 0.000 abstract description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract description 5
- 201000005202 lung cancer Diseases 0.000 abstract description 5
- 208000020816 lung neoplasm Diseases 0.000 abstract description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract description 4
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 4
- 230000003013 cytotoxicity Effects 0.000 abstract description 4
- 206010017758 gastric cancer Diseases 0.000 abstract description 4
- 201000011549 stomach cancer Diseases 0.000 abstract description 4
- 230000003993 interaction Effects 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 description 13
- 229940079593 drug Drugs 0.000 description 11
- 230000005540 biological transmission Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000000854 inhibitional effect Effects 0.000 description 1
- 239000002608 ionic liquid Substances 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G49/00—Compounds of iron
- C01G49/02—Oxides; Hydroxides
- C01G49/06—Ferric oxide [Fe2O3]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/01—Particle morphology depicted by an image
- C01P2004/04—Particle morphology depicted by an image obtained by TEM, STEM, STM or AFM
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/60—Particles characterised by their size
- C01P2004/64—Nanometer sized, i.e. from 1-100 nanometer
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The purposes of carrier is targeted the invention discloses a kind of iron oxide nano material and as tumour medicine, the iron oxide nano material is prepared via a method which: first iron chloride, polyvinylpyrrolidone and double-(3- methyl-1-imidazoles) butylidenebis disulfate being dissolved in distilled water, hydro-thermal reaction is carried out again, reaction temperature is 180-220 DEG C, reaction time is 18-22h, is finally centrifuged, washs, is dry, calcining, grinding；Wherein, the molar concentration of iron chloride is 0.03-0.04mol/L, and the concentration of polyvinylpyrrolidone is 8-12g/L, the molar concentration 0.01-0.02mol/L of double-(3- methyl-1-imidazoles) butylidenebis disulfate.Iron oxide nano material provided by the invention has the affinity of specificity to leukemia tumor cells, and may be used as the pharmaceutical carrier of selectively targeted leukemia tumor cells without obvious affinity interaction to tumour cells such as gastric cancer, lung cancer；Moreover, the iron oxide nano material to normal cell without obvious cytotoxicity, it is highly-safe.
Description
Technical field
The invention belongs to technical field of biological material, are related to pharmaceutical carrier and its preparation, and in particular to a kind of ferric oxide nano material
Material and the purposes that carrier is targeted as tumour medicine.
Background technique
Anti-tumor drug is to tumor tissues and normal cell almost non-selectivity, and generally existing curative effect is low, toxicity is big, transfer
Stove be difficult to control, patient medication poor compliance the problems such as.Therefore, anti-tumor drug transmission system has become grinding for art of pharmacy
Study carefully emphasis and hot spot.Wherein targeted delivery systems have been demonstrated to can effectively reduce the adverse reaction of anti-tumor drug, improve clinical
The compliance of curative effect and patient medication.
Nano-medicament carrier system is product of the nanometer in conjunction with modern medicine, is that one kind belongs to nanoscale pharmaceutical carrier
Transportation system, compared with traditional small-molecule drug, it is easier to be absorbed by cancer cell, can convey one or more medicines simultaneously
Object improves the dissolubility and stability of drug, adjusts the rate of release of drug, realizes drug to the actively or passively target of tumour
To improving the utilization rate of drug, reduce drug to the toxic side effect of normal cell or tissue.
Inorganic nano-particle preparation method is simple, stable structure, is one of first choice of pharmaceutical carrier.And iron oxide therein
Nanoparticle have the characteristics that corrosion resistance, it is low in cost, prepare simple, environmental-friendly, especially its biodegradability
Develop ferric oxide nano particles adequately in Nano medication field.
But although existing targeting vector has targeting to tumour cell, do not have to different tumour cells
Selective, when this results in patient's progress targeted therapy to while with a variety of cancers, drug specific can not be delivered to
Certain types of tumour cell, and some active pharmaceutical ingredients only have inhibition or lethal effect to specific tumour cell.
Summary of the invention
The purpose of the present invention is to provide a kind of iron oxide nano materials of selectively targeted leukemia tumor cells, this is received
Rice material has the affinity of specificity to leukemia tumor cells, and to tumour cells such as gastric cancer, lung cancer without obvious affine work
With may be used as the pharmaceutical carrier of selectively targeted leukemia tumor cells.
The present invention is achieved by following technical solution:
A kind of iron oxide nano material, is prepared via a method which: first by iron chloride, polyvinylpyrrolidone and
Double-(3- methyl-1-imidazoles) butylidenebis disulfate is dissolved in distilled water, then carries out hydro-thermal reaction, reaction temperature 180-
It 220 DEG C, reaction time 18-22h, is finally centrifuged, washs, is dry, calcining, grinding；Wherein, the molar concentration of iron chloride is
0.03-0.04mol/L, the concentration of polyvinylpyrrolidone are 8-12g/L, double-(3- methyl-1-imidazoles) butylidenebis hydrogen sulfate
The molar concentration 0.01-0.02mol/L of salt.
Preferably, iron chloride, polyvinylpyrrolidone and double-(3- methyl-1-imidazoles) butylidenebis disulfate are dissolved in
The reaction kettle that polytetrafluoroethylliner liner is transferred to after water carries out hydro-thermal reaction.
Preferably, the temperature of hydro-thermal reaction is 200 DEG C, reaction time 20h.
Preferably, the iron chloride is ferric chloride hexahydrate.
Preferably, ethyl alcohol and deionized water alternately washing 3-5 times, each wash volumes are the 5- of Sediment weight when washing
15 times.
Preferably, temperature when dry is 60-80 DEG C, drying time 8-12h.
Preferably, calcination temperature is 450-550 DEG C, calcination time 3-5h.
Above-mentioned iron oxide nano material is used as the purposes of the pharmaceutical carrier of selectively targeted leukemia tumor cells.
Advantages of the present invention:
Iron oxide nano material provided by the invention has the affinity of specificity to leukemia tumor cells, and to stomach
The tumour cells such as cancer, lung cancer may be used as the pharmaceutical carrier of selectively targeted leukemia tumor cells without obvious affinity interaction；And
And the iron oxide nano material to normal cell without obvious cytotoxicity, it is highly-safe.
Detailed description of the invention
Fig. 1 is the TEM transmission electron microscope picture of iron oxide nano material prepared by embodiment 1.
Specific embodiment
Substantial technical scheme of the invention is discussed in detail below with reference to embodiment.
The preparation of 1 iron oxide nano material of embodiment
It is prepared via a method which:
It is first that ferric chloride hexahydrate, polyvinylpyrrolidone and double-(3- methyl-1-imidazoles) butylidenebis disulfate is molten
In distilled water, then it is transferred to the reaction kettle progress hydro-thermal reaction of polytetrafluoroethylliner liner, reaction temperature is 200 DEG C, the reaction time
For 20h, finally it is centrifuged, washs, is dry, calcining, grinding；Wherein, the molar concentration of ferric chloride hexahydrate is 0.035mol/L, is gathered
The concentration of vinylpyrrolidone is 10g/L, the molar concentration of double-(3- methyl-1-imidazoles) butylidenebis disulfate
0.015mol/L。
Wherein, ethyl alcohol and deionized water alternately washing 4 times, each wash volumes are 10 times of Sediment weight when washing；
Temperature when dry is 70 DEG C, drying time 10h；Calcination temperature is 500 DEG C, calcination time 4h.
Fig. 1 is the TEM transmission electron microscope picture of the iron oxide nano material, it is seen that the nano material is in subsphaeroidal, dispersion degree height.
The preparation of 2 iron oxide nano material of embodiment
It is prepared via a method which:
It is first that ferric chloride hexahydrate, polyvinylpyrrolidone and double-(3- methyl-1-imidazoles) butylidenebis disulfate is molten
In distilled water, then it is transferred to the reaction kettle progress hydro-thermal reaction of polytetrafluoroethylliner liner, reaction temperature is 180 DEG C, the reaction time
For 22h, finally it is centrifuged, washs, is dry, calcining, grinding；Wherein, the molar concentration of ferric chloride hexahydrate is 0.03mol/L, is gathered
The concentration of vinylpyrrolidone is 8g/L, the molar concentration 0.01mol/ of double-(3- methyl-1-imidazoles) butylidenebis disulfate
L。
Wherein, ethyl alcohol and deionized water alternately washing 3 times, each wash volumes are 15 times of Sediment weight when washing；
Temperature when dry is 60 DEG C, drying time 12h；Calcination temperature is 450 DEG C, calcination time 5h.
The TEM transmission electron microscope picture and embodiment 1 of the iron oxide nano material of embodiment preparation are almost the same.
The preparation of 3 iron oxide nano material of embodiment
It is prepared via a method which:
It is first that ferric chloride hexahydrate, polyvinylpyrrolidone and double-(3- methyl-1-imidazoles) butylidenebis disulfate is molten
In distilled water, then it is transferred to the reaction kettle progress hydro-thermal reaction of polytetrafluoroethylliner liner, reaction temperature is 220 DEG C, the reaction time
For 18h, finally it is centrifuged, washs, is dry, calcining, grinding；Wherein, the molar concentration of ferric chloride hexahydrate is 0.04mol/L, is gathered
The concentration of vinylpyrrolidone is 12g/L, the molar concentration of double-(3- methyl-1-imidazoles) butylidenebis disulfate
0.02mol/L。
Wherein, ethyl alcohol and deionized water alternately washing 5 times, each wash volumes are 5 times of Sediment weight when washing；It is dry
Temperature when dry is 80 DEG C, drying time 8h；Calcination temperature is 550 DEG C, calcination time 3h.
The TEM transmission electron microscope picture and embodiment 1 of the iron oxide nano material of embodiment preparation are almost the same.
Embodiment 4 and embodiment 1 compare, and do not add double-(3- methyl-1-imidazoles) butylidenebis disulfate
It is prepared via a method which:
First ferric chloride hexahydrate, polyvinylpyrrolidone are dissolved in distilled water, then are transferred to the anti-of polytetrafluoroethylliner liner
Kettle is answered to carry out hydro-thermal reaction, reaction temperature is 200 DEG C, reaction time 20h, is finally centrifuged, washs, is dry, calcining, grinding；
Wherein, the molar concentration of ferric chloride hexahydrate is 0.035mol/L, and the concentration of polyvinylpyrrolidone is 10g/L.
Wherein, ethyl alcohol and deionized water alternately washing 4 times, each wash volumes are 10 times of Sediment weight when washing；
Temperature when dry is 70 DEG C, drying time 10h；Calcination temperature is 500 DEG C, calcination time 4h.
The TEM transmission electron microscope picture and embodiment 1 of the iron oxide nano material of embodiment preparation are almost the same, but nanometer
The partial size of grain is relatively small, diameter about 50nm.
Embodiment 5 and the compatibility of tumour cell measure
Reference literature method [preparation of cancer target carrier N- n-octyl-N '-succinyl group chitosan and structural characterization,
China Medicine University's journal, the 1st phase of volume 38 in 2007] it is measured, the specific method is as follows:
K562 tumour cell (leukaemia), the A549 tumour cell (lung cancer), MGC-803 tumour of logarithmic growth phase respectively
Cell (gastric cancer) is placed in culture plate, and cell concentration is 5 × 104A/mL.Each tumour cell sets two groups respectively: blank
Control group and dosing group, dosing group add the ferric oxide nano of the embodiment 1-4 preparation of fluorescein isothiocynate (FITC) label
Material, final concentration of 10mg/L, blank control group do not add the nano material.After dosing, culture plate is placed in 37 DEG C, 5%CO2
After cultivating 48h in incubator, cell is collected, is cleaned with PBS, flow cytometer detects the fluorescence intensity of cell.
The method of marked by fluorescein isothiocyanate iron oxide nano material are as follows: the iron oxide for respectively preparing embodiment 1-4
Nanoparticle and fluorescein isothiocynate are added in deionized water, and 4 DEG C of low temperature filter after stirring 12 hours, are washed with water 3 times i.e.
?.The additive amount of iron oxide nano-granule is 10g/L, and the additive amount of fluorescein isothiocynate is 15g/L.
Calculate separately the iron oxide nano material that above-mentioned three kinds of tumour cells are marked using above-mentioned FITC treated fluorescence
Multiple of the intensity relative to blank control, as a result as shown in table 1 (n=3).
The iron oxide nano material that 1 tumour cell of table is marked through FITC treated fluorescence intensity is relative to blank control
Multiple
| K562 tumour cell | A549 tumour cell | MGC-803 tumour cell | |
| Embodiment 1 | 15.2±2.7 | 2.9±0.6 | 3.5±0.7 |
| Embodiment 2 | 14.6±2.8 | 2.4±0.7 | 3.3±0.9 |
| Embodiment 3 | 14.9±2.3 | 2.5±0.5 | 3.4±0.7 |
| Embodiment 4 | 3.1±0.9 | 2.4±0.8 | 3.7±0.8 |
As it can be seen from table 1 compared with A549 tumour cell, MGC-803 tumour cell, the oxidation of embodiment 1-3 preparation
Ferrum nano material has apparent affine selectivity to K562 tumour cell；Compared with Example 4, the oxygen of embodiment 1-3 preparation
Changing ferrum nano material has apparent affine selectivity to K562 tumour cell.In this selectivity and hydrothermal reaction process whether
It is related to add double-core ionic liquid pair-(3- methyl-1-imidazoles) butylidenebis disulfate.
The safety of 6 iron oxide nano material of embodiment
According to the cytotoxicity of GB/T 16886.5-2003 test material, material is investigated using mtt assay and is directly connect with cell
Touch the influence generated to cell.Operating procedure: it by the culture of L929 l cell in RPMI-1640 culture solution, is added
Sterilized sample (nano material of embodiment 1-3 preparation, 1mL culture medium in add 1mg nano material), and it is configured to 1
×104The cell suspension of a/mL is put into 37 DEG C, 5%CO2Incubator in cultivate a week respectively.Then in every Kong Zhongjia
Enter the MTT solution and 100 μ L cell culture fluids of 50 μ L 5mg/mL, then continues to cultivate 4h in the incubator.It is molten then to suck MTT
100 μ L DMSO are added in liquid and cell culture fluid, every hole, and using microplate reader in wavelength is measurement absorbance value at 490nm, according to
Absorbance value calculates cell opposite proliferation rate:
Opposite proliferation rate (%)=experimental group OD value/negative control group OD value × 100%.
Every group of sample carries out 5 groups in parallel, is denoted as average value ± standard deviation, and statistics variance analysis uses one-way analysis
As a result method reaches 95% expression significant difference (p < 0.05).
The result shows that embodiment 1-3 group cell opposite proliferation rate is within the scope of 89.7-94.3%.According to relevant criterion,
The opposite proliferation rate of L929 cell is in 75-99% it is believed that L929 cell is not influenced by material.Therefore, embodiment 1-3 is mentioned
The cell compatibility of the iron oxide nano material of confession is preferable, has no toxic side effect.
Above-described embodiment shows that iron oxide nano material provided by the invention has specificity to leukemia tumor cells
Affinity, and selectively targeted leukemia tumor cells may be used as without obvious affinity interaction to tumour cells such as gastric cancer, lung cancer
Pharmaceutical carrier；Moreover, the iron oxide nano material to normal cell without obvious cytotoxicity, it is highly-safe.
Claims (5)
1. a kind of iron oxide nano material is used as the purposes of the pharmaceutical carrier of selectively targeted leukemia tumor cells, feature exists
In the iron oxide nano material is prepared by the following method: first by iron chloride, polyvinylpyrrolidone and double-(3- methyl-
1- imidazoles) butylidenebis disulfate is dissolved in distilled water, then carries out hydro-thermal reaction, and reaction temperature is 180-220 DEG C, when reaction
Between be 18-22h, be finally centrifuged, wash, is dry, calcining, grinding；Wherein, the molar concentration of iron chloride is 0.03-0.04mol/
L, the concentration of polyvinylpyrrolidone are 8-12g/L, the molar concentration of double-(3- methyl-1-imidazoles) butylidenebis disulfate
0.01-0.02mol/L；Wherein: iron chloride, polyvinylpyrrolidone and double-(3- methyl-1-imidazoles) butylidenebis disulfate
It is dissolved in and is transferred to the reaction kettle of polytetrafluoroethylliner liner after water and carries out hydro-thermal reaction.
2. purposes according to claim 1, it is characterised in that: the iron chloride is ferric chloride hexahydrate.
3. purposes according to claim 1, it is characterised in that: ethyl alcohol and deionized water alternately washing 3-5 times when washing,
Each wash volumes are 5-15 times of Sediment weight.
4. purposes according to claim 1, it is characterised in that: drying temperature is 60-80 DEG C, drying time 8-12h.
5. purposes according to claim 1, it is characterised in that: calcination temperature is 450-550 DEG C, calcination time 3-5h.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710564413.6A CN107324399B (en) | 2017-07-12 | 2017-07-12 | A kind of iron oxide nano material and the purposes as tumour medicine targeting carrier |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710564413.6A CN107324399B (en) | 2017-07-12 | 2017-07-12 | A kind of iron oxide nano material and the purposes as tumour medicine targeting carrier |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107324399A CN107324399A (en) | 2017-11-07 |
| CN107324399B true CN107324399B (en) | 2019-04-23 |
Family
ID=60196936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710564413.6A Active CN107324399B (en) | 2017-07-12 | 2017-07-12 | A kind of iron oxide nano material and the purposes as tumour medicine targeting carrier |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107324399B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1709271A (en) * | 2005-06-22 | 2005-12-21 | 东南大学 | Method for preparing target magnetic nano drug for treating leucosis |
| CN101080240A (en) * | 2004-12-17 | 2007-11-28 | 皇家飞利浦电子股份有限公司 | Targeting contrast agents or targeting therapeutic agents for molecular imaging and therapy |
| CN102000342A (en) * | 2010-11-23 | 2011-04-06 | 扬州大学 | Preparation method of superparamagnetism conductive nano gamma-ferric oxide/ polyaniline-dexamethasone sodium phosphate |
-
2017
- 2017-07-12 CN CN201710564413.6A patent/CN107324399B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101080240A (en) * | 2004-12-17 | 2007-11-28 | 皇家飞利浦电子股份有限公司 | Targeting contrast agents or targeting therapeutic agents for molecular imaging and therapy |
| CN1709271A (en) * | 2005-06-22 | 2005-12-21 | 东南大学 | Method for preparing target magnetic nano drug for treating leucosis |
| CN102000342A (en) * | 2010-11-23 | 2011-04-06 | 扬州大学 | Preparation method of superparamagnetism conductive nano gamma-ferric oxide/ polyaniline-dexamethasone sodium phosphate |
Non-Patent Citations (3)
| Title |
|---|
| 不同形貌a-Fe2O3的水热法制备及性能研究;涂盛辉;《材料导报B：研究篇》;20161031;第30卷(第10期);第44-48页 |
| 基于咪唑类离子液体的液相法制备a-Fe2O3纳米材料;谢淑婷;《中国优秀硕士学位论文全文数据库 工程科技I辑》;20160215;第50-53页 |
| 长春新碱超顺磁性氧化铁纳米粒的制备及体外评价;姚娟等;《中国药科大学学报》;20121231;第43卷(第3期);第222-225页 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107324399A (en) | 2017-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106139144B (en) | A kind of hyaluronic acid decorated gold-Nano carbon balls and the preparation method and application thereof with synergistic antitumor characteristic | |
| Radziun et al. | Assessment of the cytotoxicity of aluminium oxide nanoparticles on selected mammalian cells | |
| Salar et al. | Synthesis and characterization of vincristine loaded folic acid–chitosan conjugated nanoparticles | |
| CN104788670B (en) | A kind of double responsiveness glucosan polyamino acid block copolymer and preparation method thereof and carrier micelle | |
| CN104758930B (en) | A kind of preparation method and applications based on magnetic oxygenated graphene situ-gel | |
| Cao et al. | Surface PEGylation of MIL-101 (Fe) nanoparticles for co-delivery of radioprotective agents | |
| CN106552269B (en) | A kind of pH responsive type Fe3O4@LDH loads the Nano medication particle of methotrexate (MTX), preparation method and applications | |
| CN102643361B (en) | Nano selenium micromolecular microbial polysaccharide as well as preparation method and application thereof | |
| Wydra et al. | Synthesis and characterization of PEG-iron oxide core-shell composite nanoparticles for thermal therapy | |
| CN102319436A (en) | O-carboxymethyl chitosan-deoxycholic acid complex of modified with folic acid and preparation method thereof and application | |
| Dai et al. | SiO2-coated magnetic nano-Fe3O4 photosensitizer for synergistic tumour-targeted chemo-photothermal therapy | |
| CN105030795A (en) | Nanometer drug-loading system as well as preparation method and application thereof | |
| Woźniak et al. | In vitro genotoxicity and cytotoxicity of polydopamine-coated magnetic nanostructures | |
| CN103976956A (en) | Targeted anti-hepatoma nanoparticle and preparation method and application thereof | |
| CN103893777A (en) | Preparation method of hyaluronic acid targeted carbon nano-tube loaded anti-cancer medicine | |
| CN109260177A (en) | A kind of preparation method and applications of Berberine hydrochloride complex nanometer granule | |
| CN107952081B (en) | PH controlled-release target medicament nano transport agent and its preparation method and application | |
| CN107324308B (en) | A kind of mesoporous carbon nanoparticle of core-shell structure and purposes as paclitaxel carrier | |
| Teng et al. | Intracellular RNA and nuclear DNA-dual-targeted tumor therapy via upconversion nanoplatforms with UCL/MR dual-mode bioimaging | |
| Fan et al. | The structural and surface properties of Al-doped hydroxyapatite (Ca5 (PO4) 3OH) nanorods and their applications for pH-induced drug delivery | |
| Amina et al. | Synthesis of diosgenin conjugated gold nanoparticles using algal extract of Dictyosphaerium sp. and in-vitro application of their antiproliferative activities | |
| CN104146946A (en) | Oxidized graphene medicine-carried composite material for liver cancer targeting and preparation method of composite material | |
| CN103908978B (en) | Folic acid-nano-TiO 2composite photo-catalyst and preparation method and application | |
| Mahmoudi et al. | Preparation of Fe3O4/Ag3VO4/Au nanocomposite coated with Caerophyllum macropodum extract modified with oleic acid for theranostics agent in medical imaging | |
| CN107324399B (en) | A kind of iron oxide nano material and the purposes as tumour medicine targeting carrier |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20190301 Address after: 211505 D building, 9 Chuang Chuang Road, Zhongshan science and Technology Park, Liuhe District, Nanjing, Jiangsu. Applicant after: Cui Changyou Address before: 211198 1009 Tianyuan East Road, Gao Xin Garden, Jiangning District, Nanjing, Jiangsu. Applicant before: Nanjing life bearing Mstar Technology Ltd |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20190319 Address after: 226152 165 South Renmin Road, Hadong Town, Haimen, Nantong, Jiangsu Applicant after: Haimen he d Intellectual Property Service Co. Ltd. Address before: 211505 D building, 9 Chuang Chuang Road, Zhongshan science and Technology Park, Liuhe District, Nanjing, Jiangsu. Applicant before: Cui Changyou |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |